Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder

Laux, Gerd; Classen, Wilhelm; Sofić, E.; Becker, T; Riederer, Peter; Lesch, Klaus‐Peter; Struck, Michael; Beckmann, H.

doi:10.1007/978-3-7091-9113-2_28

Cited by 7 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the 1980s, controlled studies provided evidence that MAOIs are very effective in the treatment of so-called therapy-resistant depressions, atypical depressions, phobias, panic disorders and anxiety states (3,4). In addition, factors such as low cardiotoxicity, absence of anticholinergic side-effects and mood-activating properties may represent advantages of MAOIs over tricyclic antidepressants (5).…”

Section: Introductionmentioning

confidence: 99%

A double‐blind randomized placebo‐controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression

Wilde¹,

Geerts

Dorpe

et al. 1996

Acta Psychiatr Scand

View full text Add to dashboard Cite

The efficacy and safety of pirlindole (300 mg/day), a new reversible inhibitor of monoamine oxidase A, have been evaluated in a multicentre placebo-controlled double-blind randomized trial in 103 in-patients suffering from unipolar major depression (DSM-III-R 296.2, 296.3) over a 42-day period after a run-in placebo period of 6 days. Pirlindole produced a significantly greater decrease than placebo in the Hamilton depression score (from day 28), the Hamilton anxiety score (from day 28) and the Montgomery-Asberg depression score (on day 42). On day 42, the Hamilton depression score was < or = 7, > or = 8 and < or = 15, or > or = 16 in 21%, 45% and 34%, respectively, in the placebo group compared to 72%, 24% and 3.4%, respectively, in the pirlindole group (P < 0.001). The differences between the two groups in terms of tolerance and safety were not statistically significant.

show abstract

Section: Introductionmentioning

confidence: 99%

A double‐blind randomized placebo‐controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression

Wilde¹,

Geerts

Dorpe

et al. 1996

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive and anxiety disorders and in neurology for the treatment of Parkinson's disease and Alzheimer's disease [1][2][3] . Honey, pollen and propolis are all natural bee products, new therapeutic characteristics of which are emerging every day.…”

Section: Introductionmentioning

confidence: 99%

Total monoamine oxidase (MAO) inhibition by chestnut honey, pollen and propolis

Yıldız

Karahalil

Can

et al. 2013

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Monoamine oxidase (MAO) inhibitors are generally used in the treatment of depressive disorders and some neurodegenerative illnesses, such as Parkinson's disease and Alzheimer's disease. The aim of this preliminary study was to investigate the MAO [MAO (E.C.1.4.3.4)] inhibiting effect of various apitherapeutic products, such as chestnut honey, pollen and propolis. Extracts' MAO inhibition was measured using peroxidase-linked spectrophotometric assay in enzyme isolated from rat liver microsomes, and the values are expressed as the inhibition concentration (IC 50 ) causing 50% inhibition of MAO. The antioxidant activity of the bee products was also determined in terms of total phenolic content (TPC) and ferric reducing/ antioxidant power in aquatic extracts. All samples exhibited substantial inhibition of MAO, propolis having the highest. Inhibition was related to samples' TPCs and antioxidant capacities. These results show that bee products possess a sedative effect and may be effective in protecting humans against depression and similar diseases.

show abstract

“…When considering efficacy, there is now ample evidence to show that the reversible MAOA inhibitors are effective antidepressants and are as efficacious as the tricyclic reuptake inhibitors (eg see Laux et al, 1989;Kissling et al, 1989;Moller et al, 1989). Since the irreversible MAOIs were often administered at doses below the therapeutic threshold because of the risk of adverse side-effects, the reversible MAOA inhibitors can be generally regarded as more efficacious in real terms than the first generation drugs.…”

Section: Monoamine Oxidase Inhibitorsmentioning

confidence: 99%

“…Consequently, the second generation MAOIs may provide a genuine alternative for patients who do not improve when receiving monoamine reuptake inhibitors. The only question concerning the efficacy of the reversible MAOA inhibitors is whether the effect is maintained after long-term treatment (Laux et al, 1989;Udabe et al, 1989) and this issue needs to be meaningfully resolved.…”

Section: Monoamine Oxidase Inhibitorsmentioning

confidence: 99%